The U.S. government is divesting from mRNA vaccines, but will other uses of the technology be spared? In a time of ...

A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes ...

CRISPR Therapeutics (CRSP) recently showcased new preclinical results for its CTX460 therapy, revealing strong gene and mRNA correction in animal models for Alpha-1 Antitrypsin Deficiency. The ...

If you think last week's decision by the federal government to halt $500 million in funding for vaccine development projects that use mRNA technology will only affect COVID vaccines, think again.

CREATE Medicines, Inc. (formerly Myeloid Therapeutics) today announced new preclinical data for RetroT, the company's fully RNA-encoded, site-specific gene-integration system, presented at the Cold ...

SAN DIEGO & BRISBANE, Calif.--(BUSINESS WIRE)--VedaBio, a pioneering biotechnology company transforming molecular detection, today announced a non-exclusive license agreement with Mammoth Biosciences, ...

Both CRSP and NTLA are advancing in vivo gene editing therapies targeting large markets, with financial stability supporting ...

CRISPR gene editing has revolutionized the field of molecular biology, offering precise, efficient, and versatile tools for genome modification. The technology has rapidly evolved beyond the original ...

By halting funding for mRNA research, the government is endangering America’s health and leadership in biomedical innovation.

Cells use mRNA to build proteins, and after years of research, scientists learned how to harness this molecule to develop effective, safe and quick-to-make vaccines. Since the advent of this Nobel ...